[Biosimilar drugs in oncology].

Related Articles

[Biosimilar drugs in oncology].

Bull Cancer. 2016 Jan 29;

Authors: Levêque D

Abstract
Biosimilar drugs are biologic drugs clinically similar to the reference products. They correspond to a generic approach applied to biologic agents. Biosimilars are aimed to provide cheaper drugs by enhancing the concurrency. The approval of biosimilars is abbreviated when compared to that of the reference biologics but includes clinical trials (distinguishing them from the generics). Current available biosimilars in oncology are filgrastim and epoietin alpha. In the next future, will be launched rituximab and trastuzumab. In France, the development of biosimilars is faced with many hurdles that necessitates a better information of physicians and a greater price discount in the out-patient setting. More globally, harmonisation of recommendations particularly concerning extrapolation of indications and nomenclature are needed for a better acceptance.

PMID: 26832422 [PubMed - as supplied by publisher]

from Cancer via ola Kala on Inoreader http://ift.tt/23IJ1TG
via IFTTT